- Home
- NCV vs PROK Comparison
NCV vs PROK Comparison
Compare NCV & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- PROK
- Stock Information
- Founded
- NCV 2003
- PROK 2015
- Country
- NCV United States
- PROK United States
- Employees
- NCV N/A
- PROK N/A
- Industry
- NCV Finance Companies
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCV Finance
- PROK Health Care
- Exchange
- NCV Nasdaq
- PROK Nasdaq
- Market Cap
- NCV 326.0M
- PROK 384.2M
- IPO Year
- NCV N/A
- PROK N/A
- Fundamental
- Price
- NCV $14.50
- PROK $2.36
- Analyst Decision
- NCV
- PROK Buy
- Analyst Count
- NCV 0
- PROK 5
- Target Price
- NCV N/A
- PROK $6.25
- AVG Volume (30 Days)
- NCV 405.1K
- PROK 3.1M
- Earning Date
- NCV 01-01-0001
- PROK 08-12-2025
- Dividend Yield
- NCV 12.48%
- PROK N/A
- EPS Growth
- NCV N/A
- PROK N/A
- EPS
- NCV N/A
- PROK N/A
- Revenue
- NCV N/A
- PROK $527,000.00
- Revenue This Year
- NCV N/A
- PROK $105.79
- Revenue Next Year
- NCV N/A
- PROK N/A
- P/E Ratio
- NCV N/A
- PROK N/A
- Revenue Growth
- NCV N/A
- PROK N/A
- 52 Week Low
- NCV $2.84
- PROK $0.46
- 52 Week High
- NCV $3.59
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- NCV 59.98
- PROK 45.54
- Support Level
- NCV $14.33
- PROK $2.15
- Resistance Level
- NCV $14.55
- PROK $2.46
- Average True Range (ATR)
- NCV 0.15
- PROK 0.34
- MACD
- NCV -0.00
- PROK -0.13
- Stochastic Oscillator
- NCV 86.75
- PROK 15.00
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.